Insight

Yan Leyfman

Jun 12, 2025, 14:10

Yan Leyfman: Breakthrough in Solid Tumor CAR T Therapy

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:

“Breakthrough in Solid Tumor CAR T Therapy!

The first-ever RCT of CAR T-cell therapy in solid tumors shows promise!

Satri-cel (CT041), a CLDN18.2-specific CAR T-cell therapy, significantly improved PFS in patients with advanced gastric or gastro-oesophageal junction cancer vs standard treatments.

– Median PFS: 3.25 mo vs 1.77 mo
– HR: 0.37, p < 0.0001
– Manageable safety profile despite high-grade AEs

These pivotal Phase 2 data support satri-cel as a new third-line option in a population with limited alternatives.”

Title: Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

Journal: The Lancet

Authors: Changsong Qi, Chang Liu, Zhi Peng, Yanqiao Zhang, Jia Wei, Wensheng Qiu

Read the full article.

Solid Tumor

More posts featuring Yan Leyfman on OncoDaily.

cancer CAR T-cell therapy CAR-T therapy Chang Liu Changsong Qi Claudin-18 gastric cancer gastro-oesophageal junction cancer Jia Wei MedNews Week OncoDaily Oncology RCT solid tumor The Lancet Wensheng Qiu Yan Leyfman Yanqiao Zhang Zhi Peng

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment

ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact

Ravi B. Parikh: Is Accelerated FDA Approval 23 Times Stronger than the Traditional?

Habib Nehmé: The U.S. Market Remains Elekta’s Most Strategic and Significant One

Mohamad Mohty: DREAMM-7 Marks a Step Forward in Relapsed Myeloma